Wiley Matthew T. 4

What Happened

• Matthew T. Wiley, Chief Commercial Officer of Definium Therapeutics (DFTX), received an award of 115,000 restricted stock units (RSUs) on 2026-02-03. The RSUs were granted at no purchase price (reported acquisition price $0.00), so there was no cash transaction.

Key Details

• Transaction date: February 3, 2026; filing date: February 5, 2026 (appears timely).
• Transaction type/code: Award/Grant (A).
• Grant size: 115,000 RSUs; acquisition price reported $0.00 (grant).
• Vesting: 16 equal quarterly installments beginning June 1, 2026 — i.e., quarterly vesting over 4 years, subject to continuous service on each vesting date.
• Shares owned after the transaction: Not reported in the supplied filing details.
• Footnote: Each RSU represents a contingent right to one common share upon vesting; vesting is service-based.

Context

• RSUs are a form of equity compensation (not an open-market purchase or sale). They do not represent immediately tradeable shares and typically convert to shares (and may trigger tax) only as they vest.
• Such grants are commonly used for retention and incentive compensation; they should not be interpreted as a direct buy or sell signal.